ImmPACT Bio USA
Executives
View the org chart displaying its 24 main executives
Most searched biographies at ImmPACT Bio USA
- Sumant Ramachandra, President and Chief Executive Officer
- Cindy Xiong, Director
- Biren Amin, Director
Popular executive movements at ImmPACT Bio USA
- Han Lee has joined the company as President and Chief Financial Officer (posted on November 1 2023).
- Vikram Lamba, Chief Financial Officer and Head of Business Development, has left the company (posted on November 1 2023).
Create your alert
to follow the executive moves at ImmPACT Bio USA.
Biotechnology
ImmPACT Bio USA has 2,284 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Enlaza Therapeutics has just announced a $100 Million fundraising (posted on May 2 2024).
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
Popular contacts in Biotechnology
News
Press releases by ImmPACT Bio USA
- ImmPACT Bio to Present New Ex Vivo Preclinical Data for Bispecific Claudin 18.2/TGF-β CAR T Program at the American Society of Gene & Cell Therapy 27th Annual Meeting - ImmPACT Bio
- ImmPACT Bio to Participate at the 2024 Cell and Gene Meeting on the Med Conference - ImmPACT Bio
- ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20 Bispecific CAR T-Cell Therapy for Refractory Lupus Nephritis and Systemic Lupus Erythematosus - ImmPACT Bio
- ImmPACT Bio Recognized in BioSpace’s 2024 Best Places to Work - ImmPACT Bio
- ImmPACT Bio Appoints Han Lee, Ph.D., MBA, as President and Chief Financial Officer - ImmPACT Bio
- ImmPACT Bio to Participate in the 2023 Truist Securities BioPharma Symposium - ImmPACT Bio
- ImmPACT Bio Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting - ImmPACT Bio
- ImmPACT Bio Granted FDA Fast Track Designation for IMPT-514 for the Treatment of Both Active, Refractory Lupus Nephritis and Systemic Lupus Erythematosus - ImmPACT Bio
- ImmPACT Bio to Present at the BIO Investor Forum - ImmPACT Bio
- ImmPACT Bio to Present at Cell & Gene Meeting on the Mesa - ImmPACT Bio
- View more press releases Close
Social media about ImmPACT Bio USA
- ImmPACT Bio USA on Wikipedia, Google News & Yahoo Finance
- ImmPACT Bio USA on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Sumant Ramachandra 
Call ImmPACT Bio USA at +1 805...
